#USA #New York #OncoHost #Precision Oncology #PROphetNSCLC

OncoHost Expands Precision Oncology with New York State Permit

OncoHost, an innovative tech company dedicated to revolutionizing precision medicine through plasma proteomics and artificial intelligence, has recently achieved a significant milestone by receiving a laboratory permit from the New York State Department of Health Wadsworth Center. This commendable accomplishment allows the company to offer its cutting-edge test, PROphetNSCLC®, to physicians and patients throughout New York State, marking a crucial step in OncoHost’s expansion into the United States market.

The issuance of this permit signifies that OncoHost meets the high standards required for clinical laboratory operations in New York, a state known for its rigorous certification requirements. This validation not only reinforces OncoHost's dedication to quality, accuracy, and compliance but also enhances its credibility in the competitive landscape of precision oncology. Dr. Ofer Sharon, CEO of OncoHost, has emphasized the importance of this permit, stating, "This permit is a significant step forward in making precision oncology accessible to more patients. New York State maintains some of the most stringent laboratory certification requirements in the U.S., and meeting these standards underscores our scientific rigor, operational excellence, and dedication to clinical impact."

The Groundbreaking PROphetNSCLC® Test

The PROphetNSCLC® test, which has been available commercially since 2023, plays a pivotal role in supporting oncologists who treat patients with metastatic non-small cell lung cancer (mNSCLC). Utilizing just a single blood sample, this groundbreaking test analyzes thousands of plasma proteins, providing a personalized assessment of the likely clinical benefit from PD-1/PD-L1 inhibitors. This innovative approach empowers physicians to make more informed treatment decisions, ultimately leading to better patient outcomes.

Dr. Amir Gelman, Director of Laboratory Operations and Assay Development at OncoHost, shared his insights on the impact of this permit, stating, "Receiving this permit allows us to serve one of the nation's largest and most diverse patient populations. We're proud to deliver reliable, high-quality testing that supports oncologists in making data-driven decisions for their patients."

Enhanced Testing Capabilities

OncoHost's recent authorization adds to the company's existing certifications under the Clinical Laboratory Improvement Amendments (CLIA), along with accreditation from the College of American Pathologists (CAP). This combination strengthens OncoHost's capabilities in the U.S. testing landscape and significantly broadens its clinical reach. With the PROphetNSCLC® now officially available for clinical use across all 50 U.S. states, the company is poised to make a considerable impact in the realm of precision medicine.

A Glimpse into the Future

Looking ahead, OncoHost remains committed to improving patient outcomes through its innovative approach and advanced technology. The company’s leadership comprises experienced entrepreneurs and industry experts who guide the efforts toward precision diagnostics and biomarker development. Currently, OncoHost is supported by a large-scale prospective clinical trial that involves over 40 sites and has recruited 1,700 patients globally, positioning the company at the forefront of advancements in personalized cancer treatment.

As OncoHost continues on its path of innovation, the recent permit from New York State represents a significant step in its mission to enhance accessibility to precision medicine, ensuring that more patients benefit from state-of-the-art therapeutic strategies. To learn more about OncoHost and its offerings, visit www.oncohost.com or connect with them on social media platforms like LinkedIn, Twitter, Facebook, and YouTube.